With drug-diagnostic co-development partnerships fueling advances in diagnostic testing for Alzheimer’s, Multiple Sclerosis, cardiovascular disease, rare genetic disorders, and cancer, 2025 is poised as a critical year for Europe’s precision medicine community. However, developing, clinically validating, regulatory filing and commercialising biomarkers and in vitro diagnostics remains no easy feat, as knowledge gaps persist in validating surrogate endpoints, co-developing scalable diagnostic testing workflows and infrastructure, navigating reimbursement pathways, and harmonising drug-diagnostic IVDR-adherence for approval in unmet patient need.

The 15th World Clinical Biomarkers and Companion Diagnostics Summit Europe returns as the industry-leading end-to-end forum for Europe’s precision medicine community. Serving as your premium connection-making platform, this summit will unite over 170 key European stakeholders to accelerate precision drugs from discovery through to commercialisation for patients in need.

Time: 5:00 PM – 5:00 PM

Venue details: The Minster Building, 21 Mincing Lane, London, England, EC3R 7AG, United Kingdom

Prices: GBP 0.50 – GBP 3099.00

Speakers: Andrea Stevens, Senior Director Precision Medicine Access, Johnson and Johnson Innovative Medicine, Anne-Laure Bauchet, Immunohistochemistry Team Manager and Translational Medicine Lead, Sanofi, Annick Sawala, Head of Translational Research, Vivan Therapeutics, Antje Lukas, Senior Director, Regulatory Affairs Companion Diagnostics, Daiichi Sankyo Europe, Catarina Veiga, Commercial Director, Pharma Business, Platomics, and more